REG - N4 Pharma PLC - Exercise of Warrants and Issue of Equity
RNS Number : 2259WN4 Pharma PLC14 August 202014 August 2020
N4 Pharma plc
("N4 Pharma" or the "Company")
Exercise of Warrants and Issue of Equity
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that it has received notification to exercise warrants representing 112,500 ordinary shares of 0.4 pence each ("Ordinary Shares") in the Company for total consideration of £4,500.
Application has been made for the 112,500 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on or around 20 August 2020. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Company does not hold any Ordinary Shares in treasury.
Following Admission and for the purposes of the Disclosure Guidance and Transparency Rules, the Company's total issued share capital will consist of 152,306,287 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.
Enquiries:
N4 Pharma plc
Nigel Theobald, CEO
Via Scott PR
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP
Tel: +44(0)20 3470 0470
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Turner Pope Investments (TPI) Limited
Tel: +44(0)20 3657 0050
Joint Broker
Andy Thacker
Scott PR
Georgia Smith
Tel: +44(0)1477 539 539
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDIOEFLFLVTTISLII
Recent news on N4 Pharma
See all newsREG - N4 Pharma PLC - Posting of Annual Report & Notice of AGM
AnnouncementRCS - N4 Pharma PLC - N4 Pharma Webinar on SRI Collaboration
AnnouncementREG - N4 Pharma PLC - Collaboration Agreement with SRI International Inc
AnnouncementREG - N4 Pharma PLC - Final Results
AnnouncementREG - N4 Pharma PLC - Oral Delivery Update
Announcement